Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis

Abstract

Importance: Long-term sleep disturbances in menopausal women are closely related to cardiovascular disorders, metabolic disorders, and cognitive impairment. At present, hormone therapy (HT) is a standard treatment for menopausal symptoms. However, it remains unclear whether HT can improve sleep quality. Objective: We did a systematic review and meta-analysis to assess the effects of different HT regimens on menopausal sleep quality. Evidence Review: We systematically searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, PsycINFO, CINAHL, and Web of Science for randomized controlled trials of menopausal HT on sleep disturbances up to June 14,2021. Information about ongoing and unpublished trials was collected by searching WHOICTRP and ClinicalTrials.gov. Our primary outcome was sleep quality with objective measurements. We estimated the standardized mean difference (SMD) using random-effects models. Findings: We identified a total of 3,059 studies and finally included 15 studies in the meta-analysis. Compared with placebo, HT improved self-reported sleep outcomes (SMD = –0.13; 95% CI, –0.18 to -0.08, P < 0.00001 and I 2 = 41%), but not sleep parameters measured by polysomnography. Subgroup analyses according to the regimen of HT showed that 17β-estradiol (17β-E 2 ) (SMD = –0.34; 95% CI, –0.51 to -0.17, P < 0.0001, and I 2 = 0%) and conjugated equine estrogens (SMD = –0.10; 95% CI, −0.12 to −0.07, P < 0.00001, and I 2 = 0%) improved sleep quality. Moreover, transdermal administration (SMD = −0.35; 95% CI, −0.64 to −0.06, and P = 0.02) was more beneficial than oral (SMD = −0.10; 95% CI, −0.14 to −0.07, and P < 0.00001). In addition, the combination of estrogen and progesterone had a positive effect on sleep disturbance (SMD = −0.10; 95% CI, −0.13 to −0.07, P < 0.00001, and I 2 = 0%), while estrogen monotherapy did not. The results showed that estrogen/micronized progesterone (SMD = −0.22; 95% CI, −0.37 to −0.06, P = 0.007, and I 2 = 0%) and estrogen/medroxyprogesterone acetate (SMD = −0.10; 95% CI, −0.13 to −0.07, P < 0.00001, and I 2 = 0%) could alleviate sleep disturbance. Conclusions and Relevance: HT has a beneficial effect on sleep disturbance to some extent, and the formulations and routes of administration of hormonal agents influence the effect s...

Factors affecting climacteric women with SARS-CoV-2 infection: A multinational Latin America study (REDLINC XI)

“…However, in severe disease forms, hypnotic treatment was associated with a significantly favorable outcome [31]. The deterioration of sleep quality is linked to the climacteric and some studies have shown improvement with MHT [32,33]. For this reason, the use of hypnotics could be considered a surrogate marker of the hypoestrogenism typical of menopause, a factor associated with a higher risk of presenting COVID-19.…”

Sleep disturbances in women with early-onset menopausal transition: a population-based study

“…Previous studies on menopause, vasomotor symptoms, sleep, and HT use have mainly focused on women experiencing menopause by the age of 50 years or older. 45 Our results indicate that sleep disturbances in women in their mid-40s may not be recognized as being associated with early-onset menopausal transition and may therefore go untreated with HT.…”

The role of diet in managing menopausal symptoms: A narrative review

“…Clinical guidelines and expert statements for menopausal sleep disturbances in North America and the United Kingdom recommend offering advice on sleep hygiene (NICE, 2022; Shea et al, 2021), a set of behaviours and environmental factors to promote better quality sleep and cognitive behavioural therapy (Shea et al, 2021). Hormone therapies, including 17β‐oestradiol and combined oestrogen and progesterone, are also reported to have a beneficial effect (Cheng et al, 2021; Pan et al, 2022).…”